Xiang Ling
Assistant Professor
Department of Pharmacology & Therapeutics
Roswell Park Cancer Institute
United States of America
Biography
Dr. Xiang Ling works as Assistant Professor of Oncology in the Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. He also works as associate member for Molecular Pharmacology and Cancer Therapeutics Graduate Program and Experimental Therapeutics CCSG (Comprehensive Cancer Support Grant) Program. The main focus of our research is: Role of survivin and its splice variants in tumorigenesis and cancer treatment, Mechanisms of anticancer drug resistance, Anti-cancer drug discovery, development and molecular mechanism of action studies.
Research Interest
Role of survivin and its splice variants in tumorigenesis and cancer treatment, Mechanisms of anticancer drug resistance, Anti-cancer drug discovery, development and molecular mechanism of action studies.
Publications
-
Ling X, Cao S, Cheng Q, Keefe JT, Rustum, YM, et al. (2012) A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity 7: 45571
-
Ling X, Cheng QY, Black JD, Li F, (2007) Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax and survivin. J Biol Chem 282: 27204-14
-
Ling X, Bernacki RJ, Brattain MG, Li F, (2004) Induction of survivin expression by taxol (taxane paclitaxel) is an early event and is independent of taxol-mediated mitotic arrest. J Biol Chem 279: 15196-15203
